Helicobacter Pylori Culture and Antimicrobial Resistance in Iran
Overview
Affiliations
Objective: Helicobacter pylori is considered as an important etiologic factor in pathogenesis of peptic ulcer disease, chronic gastritis and gastric cancer. To eradicate this micro-organism, numerous regimens containing various antimicrobial agents have been suggested. However, H pylori antimicrobial resistance is a leading factor to treatment failure and recurrence of the disease. The aim of the study was to evaluate the prevalence of H pylori resistance to metronidazole, clarithromycin, tetracycline, amoxicillin, erythromycin and furazolidone in authors pediatric patients.
Methods: Antral biopsy of all pediatric patients with negative history of receiving anti-H pylori regimen and endoscopic findings of nodular gastritis or peptic ulcer without previous history of NSAID consumption, burning and trauma were performed for H pylori histology, urease test and culture. All positive cultures were tested for antimicrobial susceptibility.
Results: Twenty four patients (14 male and 10 female) between 3.5 and 14 years of age were culture positive. 54.16% of the isolates were resistant to metronidazole, 8.33% to amoxicillin, 4.16% to erythromycin and 4.16% to clarithromycin. None of authors patients were resistant to tetracycline and furazolidone.
Conclusion: H. pylori antimicrobial resistance could be a major contributor to failure of H pylori eradication. Continuous prospective surveillance of H. Pylori is essential. Moreover, culture and antimicrobial susceptibility test is recommended for resistant cases after the first failure to therapy.
Salahi-Niri A, Nabavi-Rad A, Monaghan T, Rokkas T, Doulberis M, Sadeghi A BMC Med. 2024; 22(1):598.
PMID: 39710669 PMC: 11664859. DOI: 10.1186/s12916-024-03816-y.
Kazemi Veysari A, Rahimi A, Maleki I, Tirgar Fakheri H, Taghvaei T, Hosseini V Caspian J Intern Med. 2023; 14(4):676-680.
PMID: 38024162 PMC: 10646372. DOI: 10.22088/cjim.14.4.676.
Kouitcheu Mabeku L, Bille B, Tepap Zemnou C, Tali Nguefack L, Leundji H BMC Infect Dis. 2019; 19(1):880.
PMID: 31640588 PMC: 6806547. DOI: 10.1186/s12879-019-4536-8.
Moradniani M, Mirbeik-Sabzevari Z, Jaferian S, Shafiezadeh S, Ehsani Ardakani M, Mirzaee Roozbahany M Gastroenterol Hepatol Bed Bench. 2018; 11(1):19-26.
PMID: 29564061 PMC: 5849114.
Resistance of to furazolidone and levofloxacin: A viewpoint.
Zamani M, Rahbar A, Shokri-Shirvani J World J Gastroenterol. 2017; 23(37):6920-6922.
PMID: 29085236 PMC: 5645626. DOI: 10.3748/wjg.v23.i37.6920.